Where Will BioNTech Be in 3 Years?
_0.png?locale=de){kind=logo}
As half of the duo behind one of the world's most widely used and effective COVID-19 vaccines, BioNTech (NASDAQ: BNTX) is well on its way to enduring stardom in the healthcare sector. Far from content to keep playing second fiddle to collaborator Pfizer (NYSE: PFE), the biotech looks to be on a path toward ever-greater independence.
But that path carries some risks. Though it'll be raking in its share of Comirnaty revenue for quite some time, -- including an estimated 13 billion euros to 17 billion euros this year -- BioNTech has yet to prove that it can develop and market a therapy or vaccine entirely on its own.
Let's make a few projections about where the business is going in the next three years so that investors can judge whether it might be a favorable investment, given that the market has already largely priced in its near-term COVID-19 vaccine income.
Source Fool.com
